Literature DB >> 17023504

Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3.

Kate S Stokoe1, Glyn Thomas, Catharine A Goddard, William H Colledge, Andrew A Grace, Christopher L-H Huang.   

Abstract

Long QT3 (LQT3) syndrome is associated with incomplete Na+ channel inactivation, abnormal repolarization kinetics and prolonged cardiac action potential duration (APD). Electrophysiological effects of flecainide and quinidine were compared in Langendorff-perfused wild-type (WT), and genetically modified (Scn5a+/Delta) murine hearts modelling LQT3. Extra stimuli (S2) following trains of pacing stimuli (S1) applied to the right ventricular epicardium triggered ventricular tachycardia (VT) in 16 out of 28 untreated Scn5a+/Delta and zero out of 12 WT hearts. Paced electrogram fractionation analysis then demonstrated increased electrogram durations (EGD), expressed as EGD ratios, in arrhythmogenic Scn5a+/Delta hearts, and prolonged ventricular effective refractory periods in initially non-arrhythmogenic Scn5a+/Delta hearts. Nevertheless, comparisons of epicardial and endocardial monophasic action potential recordings demonstrated negative transmural repolarization gradients in both groups, giving DeltaAPD(90) values at 90% repolarization of -20.88 +/- 1.93 ms (n = 11) and -16.91 +/- 1.43 ms (n = 23), respectively. Flecainide prevented initiation of VT in 13 out of 16 arrhythmogenic Scn5a+/Delta hearts, reducing EGD ratio and restoring DeltaAPD90 to + 7.55 +/- 2.24 ms (n = 9) (P < 0.05). VT occurred in four out of eight non-arrhythmogenic Scn5a+/Delta hearts in the presence of quinidine, which increased EGD ratio but left DeltaAPD90 unchanged. In contrast (P < 0.05), WT hearts had positive DeltaAPD90 values (+ 11.72 +/- 2.17 ms) (n = 20). Flecainide then increased arrhythmic tendency and EGD ratio but conserved DeltaAPD90; reduced EGD ratios and unaltered DeltaAPD90 values accompanied the lower arrhythmogenicity associated with quinidine treatment. In addition to the changes in EGD ratio shown by WT hearts, these findings attribute arrhythmogenesis and its modification by flecainide and quinidine to alterations in DeltaAPD90 in Scn5a+/Delta hearts. This is consistent with a hypothesis in which incomplete Na+ channel inactivation in Scn5a+/Delta hearts generates functional substrates dependent on altered refractoriness that cause abnormalities in activation and conduction of subsequent cardiac impulses. Any spatial heterogeneities between the epicardial and endocardial layers would thus cause fragmentation of the activation wavefront and contribute to electrogram spreading.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023504      PMCID: PMC1810389          DOI: 10.1113/jphysiol.2006.117945

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  65 in total

1.  Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Arthur J Moss; John R Windle; W Jackson Hall; Wojciech Zareba; Jennifer L Robinson; Scott McNitt; Patricia Severski; Spencer Rosero; James P Daubert; Ming Qi; Michael Cieciorka; Allan S Manalan
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

2.  Multi-center clinical experience with a lumenless, catheter-delivered, bipolar, permanent pacemaker lead: implant safety and electrical performance.

Authors:  Michael D Gammage; Randy A Lieberman; Raymond Yee; Antonis S Manolis; Steven J Compton; César Khazen; Katie Schaaf; Kimberly A Oleson; George H Crossley
Journal:  Pacing Clin Electrophysiol       Date:  2006-08       Impact factor: 1.976

Review 3.  Drug therapy for atrial fibrillation: where do we go from here?

Authors:  Richard L Page; Dan M Roden
Journal:  Nat Rev Drug Discov       Date:  2005-11       Impact factor: 84.694

Review 4.  Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.

Authors:  Wataru Shimizu; Takeshi Aiba; Charles Antzelevitch
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

5.  Quinidine plus verapamil vs. quinidine alone to prevent recurrences of atrial fibrillation.

Authors:  Henrique H Veloso; Angelo A V de Paola
Journal:  Eur Heart J       Date:  2005-05-17       Impact factor: 29.983

6.  The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient.

Authors:  Danny L Costantini; Eric P Arruda; Pooja Agarwal; Kyoung-Han Kim; Yonghong Zhu; Wei Zhu; Melanie Lebel; Chi Wa Cheng; Chong Y Park; Stephanie A Pierce; Alejandra Guerchicoff; Guido D Pollevick; Toby Y Chan; M Golam Kabir; Shuk Han Cheng; Mansoor Husain; Charles Antzelevitch; Deepak Srivastava; Gil J Gross; Chi-chung Hui; Peter H Backx; Benoit G Bruneau
Journal:  Cell       Date:  2005-10-21       Impact factor: 41.582

7.  Epicardial activation patterns of torsade de pointes in canine hearts with quinidine-induced long QT interval but without myocardial infarction.

Authors:  H Inoue; Y Murakawa; I Toda; A Nozaki; H Matsuo; S Mashima; T Sugimoto
Journal:  Am Heart J       Date:  1986-06       Impact factor: 4.749

8.  Caffeine-induced arrhythmias in murine hearts parallel changes in cellular Ca(2+) homeostasis.

Authors:  Richard Balasubramaniam; Sangeeta Chawla; Andrew A Grace; Christopher L-H Huang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-05-27       Impact factor: 4.733

9.  Delayed paced ventricular activation in the long QT syndrome is associated with ventricular fibrillation.

Authors:  Richard C Saumarez; Mariusz Pytkowski; Maciej Sterlinski; Richard N W Hauer; Richard Derksen; Martin D Lowe; Hannah Szwed; Christopher L-H Huang; David E Ward; A John Camm; Andrew A Grace
Journal:  Heart Rhythm       Date:  2006-03-16       Impact factor: 6.343

10.  Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice.

Authors:  Catherine E Head; Richard Balasubramaniam; Glyn Thomas; Catharine A Goddard; Ming Lei; William H Colledge; Andrew A Grace; Christopher L-H Huang
Journal:  J Cardiovasc Electrophysiol       Date:  2005-12
View more
  24 in total

1.  Ventricular arrhythmogenesis following slowed conduction in heptanol-treated, Langendorff-perfused mouse hearts.

Authors:  Gary Tse; Sandeep S Hothi; Andrew A Grace; Christopher L-H Huang
Journal:  J Physiol Sci       Date:  2012-01-05       Impact factor: 2.781

2.  Inhibitory effects of hesperetin on Nav1.5 channels stably expressed in HEK 293 cells and on the voltage-gated cardiac sodium current in human atrial myocytes.

Authors:  Huan Wang; Hong-Fei Wang; Hao Zhang; Chen Wang; Yu-Fang Chen; Rong Ma; Ji-Zhou Xiang; Xin-Ling Du; Qiang Tang
Journal:  Acta Pharmacol Sin       Date:  2016-10-03       Impact factor: 6.150

3.  Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.

Authors:  Larissa Fabritz; Dierk Damke; Markus Emmerich; Susann G Kaufmann; Kathrin Theis; Andreas Blana; Lisa Fortmüller; Sandra Laakmann; Sven Hermann; Elena Aleynichenko; Johannes Steinfurt; Daniela Volkery; Burkhard Riemann; Uwe Kirchhefer; Michael R Franz; Günter Breithardt; Edward Carmeliet; Michael Schäfers; Sebastian K G Maier; Peter Carmeliet; Paulus Kirchhof
Journal:  Cardiovasc Res       Date:  2010-01-28       Impact factor: 10.787

4.  Atrial arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its relationship to Na+ channel expression and cardiac conduction.

Authors:  Laila Guzadhur; Sarah M Pearcey; Rudolf M Duehmke; Kamalan Jeevaratnam; Anja F Hohmann; Yanmin Zhang; Andrew A Grace; Ming Lei; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2010-06-16       Impact factor: 3.657

5.  Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.

Authors:  Ian N Sabir; Lucia M Li; Victoria J Jones; Catharine A Goddard; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2007-09-06       Impact factor: 3.657

Review 6.  Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.

Authors:  Samantha C Salvage; Karthik H Chandrasekharan; Kamalan Jeevaratnam; Angela F Dulhunty; Andrew J Thompson; Antony P Jackson; Christopher L-H Huang
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

Review 7.  Murine Electrophysiological Models of Cardiac Arrhythmogenesis.

Authors:  Christopher L-H Huang
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

8.  A quantitative analysis of the effect of cycle length on arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts.

Authors:  Ian N Sabir; James A Fraser; Thomas R Cass; Andrew A Grace; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2007-04-17       Impact factor: 3.657

9.  Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts.

Authors:  Nina S Ghais; Yanmin Zhang; Andrew A Grace; Christopher L-H Huang
Journal:  Exp Physiol       Date:  2008-10-31       Impact factor: 2.969

Review 10.  Genetics of and pathogenic mechanisms in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Anita Kiran Vimalanathan; Elisabeth Ehler; Katja Gehmlich
Journal:  Biophys Rev       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.